The Inhibitory gamma  Subunit of the Type 6 Retinal cGMP Phosphodiesterase Functions to Link c-Src and G-protein-coupled Receptor Kinase 2 in a Signaling Unit That Regulates p42/p44 Mitogen-activated Protein Kinase by Epidermal Growth Factor*

Kah Fei Wan, Balwinder S. Sambi, Rothwelle Tate, Catherine Waters, and Nigel J. PyneDagger

From the Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 ONR, Scotland, United Kingdom

Received for publication, November 27, 2002, and in revised form, March 4, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The inhibitory gamma  subunit of the retinal photoreceptor type 6 cGMP phosphodiesterase (PDEgamma ) is phosphorylated by G-protein-coupled receptor kinase 2 on threonine 62 and regulates the epidermal growth factor- dependent stimulation of p42/p44 mitogen-activated protein kinase in human embryonic kidney 293 cells. We report here that PDEgamma is in a pre-formed complex with c-Src and that stimulation of cells with epidermal growth factor promotes the association of GRK2 with this complex. c-Src has a critical role in the stimulation of the p42/p44 mitogen-activated protein kinase cascade by epidermal growth factor, because c-Src inhibitors block the activation of this kinase by the growth factor. Mutation of Thr-62 (to Ala) in PDEgamma produced a GRK2 phosphorylation-resistant mutant that was less effective in associating with GRK2 in response to epidermal growth factor and did not potentiate the stimulation of p42/p44 mitogen-activated protein kinase by this growth factor. The transcript for a short splice variant version of PDEgamma lacking the Thr-62 phosphorylation site is also expressed in certain mammalian cells and, in common with the Thr-62 mutant, failed to potentiate the stimulatory effect of epidermal growth factor on p42/p44 mitogen-activated protein kinase. The mutation of Thr-22 (to Ala) in PDEgamma , which is a site for phosphorylation by p42/p44 mitogen-activated protein kinase, resulted in a prolonged activation of p42/p44 mitogen-activated protein kinase by epidermal growth factor, suggesting a role for this phosphorylation event in the negative feedback control of PDEgamma .

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Mitogenic stimuli initiate cell proliferation via different classes of cell surface receptors that include growth factor receptor tyrosine kinase receptors and G-protein-coupled receptors (GPCRs).1 This involves stimulation of the p42/p44 mitogen-activated protein kinase (p42/p44 MAPK) pathway (1, 2). In certain cases, growth factor- and GPCR agonist-mediated stimulation of the p42/p44 MAPK pathway require the G-protein-regulated aggregation of signaling molecules followed by endocytosis of receptor signal complexes at clathrin-coated pits via a dynamin II-dependent process (3). For instance, isoproterenol, insulin-like growth factor-1, platelet-derived growth factor, fibroblast growth factor, and nerve growth factor can sometimes use G-proteins, G-protein-coupled receptor kinase 2 (GRK2), and beta -arrestin I/II to regulate the p42/p44 MAPK pathway (4-11). GRK2 is activated by G-protein beta gamma subunits and phosphorylates GPCRs, which are, in certain cases, associated with growth factor receptors (10, 12). The phosphorylation of the GPCR promotes binding of beta -arrestin, which is required for dynamin II-dependent endocytosis of the receptor-signal complex and subsequent activation of p42/p44 MAPK (13). Thus, the expression of dominant-inhibitory beta -arrestin I or dynamin II mutants impairs insulin-like growth factor-1-, beta -adrenergic-, and lysophosphatidic acid-dependent activation of p42/p44 MAPK (14-16). In the presence of these inhibitory mutants, the p42/p44 MAPK signaling cascade proceeds only as far as Raf activation (16). beta -Arrestin is a clathrin adaptor that binds certain receptor complexes and targets them to clathrin-coated pits, whereas dynamin II is a GTPase involved in the "pinching off" of clathrin-coated endocytic vesicles containing the receptor-signal complex (17). The hydrolysis of GTP by dynamin II is believed to be catalytic for pinching off of endocytic vesicles and subsequent relocalization of receptor signal complexes with cytoplasmic MEK-1 and p42/p44 MAPK.

The phototransduction cascade involving rhodopsin (GPCR), GRK, beta -arrestin, and RGS9Gbeta 5 (18) bears many similarities with signaling by growth factors and G-protein-coupled receptors in other mammalian cell systems. The phototransduction cascade involves cGMP phosphodiesterases that are expressed in rod and cone photoreceptors (termed PDE6) as tetrameric proteins composed of two catalytic subunits and two gamma  subunits (PDEgamma ). PDEgamma inhibits cGMP hydrolysis at the catalytic sites. The two types of photoreceptor cells, rod and cone, express different isoforms of PDEgamma . These proteins differ in their extreme N-terminal regions, whereas the central polycationic and C-terminal domains that are involved in the interaction with both PDE6 and transducin are almost identical.

We have found that PDEgamma has a wider role in mammalian cell biology (19-22). Indeed, we have reported that rod PDEgamma is expressed in lung, kidney, testes, liver, heart, airway, and pulmonary smooth muscle and HEK 293 cells and is absent from these tissues in rod PDEgamma knockout mice. We have also identified a novel role for PDEgamma in regulating the EGF- and thrombin-dependent activation of the p42/p44 MAPK pathway in HEK 293 cells (21). We also found that GRK2 is required for the stimulatory effect of rod PDEgamma on both the EGF- and thrombin-dependent activation of p42/p44 MAPK. Indeed, rod and cone PDEgamma are substrates for phosphorylation by GRK2. Moreover, a GRK2 phosphorylation-resistant (Thr-62 changed to Ala) rod PDEgamma mutant failed to increase the EGF- or thrombin-dependent activation of p42/p44 MAPK, and in fact functioned as a dominant negative. We also presented evidence to show that thrombin stimulates the formation of a complex between rod PDEgamma and dynamin II (21). This is significant because it is well established that GTP hydrolysis by dynamin II promotes endocytosis of vesicles containing receptor signal complexes that subsequently relocalize with and activate cytoplasmic p42/p44 MAPK. Taken together, the data are consistent with the phosphorylation of Thr-62 in rod PDEgamma by GRK2 being essential for interaction with dynamin II.

In this paper, we have further explored the dynamic of the interaction between PDEgamma and GRK2. We show for the first time that PDEgamma is a functional linker/regulator of both c-Src and GRK2. We also show that a GRK2 phosphorylation-resistant PDEgamma mutant (Thr-62 PDEgamma mutant) is less effective than the wild type protein in binding GRK2 in response to EGF. The mutant appears to function as an endogenous dominant negative by acting as a sink for c-Src. We also provide the first evidence for a negative feedback mechanism involving p42/p44 MAPK that regulates PDEgamma and appears to limit the duration of p42/p44 MAPK activation in response to EGF.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- All biochemicals were from Roche Applied Science, whereas general chemicals were from Sigma. Cell culture supplies were from Invitrogen. Anti-phospho-p42/p44 MAPK and anti-dynamin II antibodies were from New England Biolabs. Anti-Grb-2 and anti-p42 MAPK antibodies were from Transduction Laboratories (Lexington, KY). Anti-Src and anti-GRK2 antibodies were from Santa Cruz Biotechnology. pRK5-GRK2 cDNA plasmid construct was a kind gift from Professor R. Lefkowitz (Duke University). Anti-PDEgamma antibody to the C-terminal domain of photoreceptor PDEgamma and which reacts with both rod and cone isoforms was a kind gift from Dr. R. Cote (University of New Hampshire).

Cell Culture-- HEK 293 cells were maintained in minimal essential medium containing 10% (v/v) fetal calf serum. These cells were placed in minimal essential medium for 24 h before experimentation. ASM cells were maintained in Dulbecco's modified Eagle's medium with 10% (v/v) fetal calf serum and 10% donor horse serum. These cells were placed in Dulbecco's modified Eagle's medium with 0.1% (v/v) fetal calf serum for 24 h before experimentation.

Transfection-- HEK 293 cells were transiently transfected with vector or rod PDEgamma or Thr-62 rod PDEgamma mutant pcDNA-6xHis plasmid constructs or pRK5-GRK2 plasmid constructs. Cells at 90% confluence were placed in minimal essential medium containing 2% (v/v) fetal calf serum and transfected with 2 µg of plasmid construct following complex formation with LipofectAMINETM 2000, according to the manufacturer's instructions. The cDNA-containing media were then removed following incubation for 24 h at 37 °C, and the cells were incubated for a further 24 h in serum-free medium prior to addition of epidermal growth factor. ASM cells were transiently transfected with mouse lung rod (wild type and Thr-22 mutant) PDEgamma pcDNA-3.1 plasmid constructs in Dulbecco's modified Eagle's medium with 2% (v/v) fetal calf serum for 24 h before experimentation.

Site-directed Mutagenesis-- To generate the Thr-62 (replaced with Ala) mutant, a PCR was performed using mouse lung rod PDEgamma pcDNA-3.1 plasmid construct with forward (5'-GGA AGG CCT GGG G(G)C AGA TAT CAC CGT CAT C-3') and reverse primers (5'-GAT GAC GGT GAT ATC TG(C) CCC CAG GCC TTC C-3') (Invitrogen). To generate the Thr-22 (replaced with Ala) mutant, a PCR was performed using mouse lung rod PDEgamma pcDNA-3.1 plasmid construct with forward (5'-GGA GGA CCA GTC GCC CCC AGG AAA G-3') and reverse primers (5'-C TTT CCT GGG GGC GAC TGG TCC TCC-3') (Invitrogen). Both of these sets of primers were used in a QuikChange (Stratagene) PCR. The PCR conditions were per the QuikChange manual with the following changes: 1 cycle at 95 °C for 30 s followed by 12 cycles at 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 11 min. The reaction was digested with DpnI, and a 1-µl aliquot was transformed into Top10 strain Escherichia coli (Invitrogen). Plasmid preparations were obtained from the resultant colonies and screened for the correct mutation by sequencing. The mutated insert was subcloned from pcDNA-3.1 by digesting with BamHI and HindIII and was also inserted in-frame into pTrcHis-B (Invitrogen).

HEK 293 Cell Lysates-- Stimulations of HEK 293 cells were carried out at 37 °C in serum-free medium. After stimulation, medium was removed from the monolayer cell and washed with ice-cold phosphate-buffered saline and lysed in 1 ml of buffer containing 1× phosphate-buffered saline, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM sodium orthovanadate, 2 mM PMSF, leupeptin, pepstatin, and aprotinin (all protease inhibitors were at 10 µg/ml). The lysates were passed through the 21-gauge needle to shear the DNA. The lysates were then incubated at 4 °C for 30 min. The cell lysate supernatant was then harvested by centrifugation at 10,000 × g for 10 min at 4 °C.

Recombinant His6-tagged Rod PDEgamma -- The open reading frame of mouse lung rod PDEgamma was subcloned into an expression vector pTrcHis (Invitrogen). The vector was transformed into TOP10F' E. coli strain. The E. coli was grown in 2 ml of Luria Broth (LB) containing 10% (w/v) tryptone, 5% (w/v) yeast extract, and 10% (w/v) NaCl supplemented with 50 µg/ml ampicillin at 37 °C overnight. The overnight E. coli culture was then diluted 50-fold with 100 ml of LB medium containing 50 µg/ml ampicillin and grown for an additional 2.5 h, until the A600 of the culture was 0.6-0.8. Isopropyl-beta -D-thiogalactoside was then added to a final concentration of 1 mM for induction of the culture at 30 °C. After a suitable period of induction (3 h), the cells were harvested by centrifugation (A-18C rotor Centrikon T-42K, 15 min at 7,400 rpm at 4 °C) and resuspended in lysis buffer containing 20 mM Na2HPO4, pH 7.8. Each sample was then lysed by 3 times ultrasonication followed by 3 times freeze-thaw cycles in lysis buffer. All buffers above contained protease inhibitors (20 µg/ml aprotinin, 10 µg/ml leupeptin, 2 mM benzamidine, and 0.1 mM PMSF) to inhibit proteolytic reaction in the sample. The lysed cells were then centrifuged at 13,000 rpm/10 min at 4 °C (Sigma laboratory centrifuge IK15) to remove the insoluble cell debris. The supernatant was stored at -70 °C.

Magnetocapture Assay-- Ni-NTA magnetic agarose beads (Qiagen) were resuspended by vortexing for 2 s. 500 µl of the recombinant His6-tagged rod PDEgamma was immediately added to 50 µl of the 5% (w/v) Ni-NTA magnetic agarose beads suspension. The suspension was incubated on an end-over-end shaker for 1 h at 4 °C. This was to allow efficient binding of the His-tagged rod PDEgamma to the Ni-NTA magnetic agarose beads. After 1 h, the microcentrifuge tubes containing the complexes were placed on a 12-tube magnetic separator for 1 min, and the supernatant was removed with a pipette. The magnetic beads-His-tagged rod PDEgamma complexes were washed with wash buffer (50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole, pH 8.0) for 3 times at 4 °C, and the wash buffer was removed by placing the microcentrifuge tubes on the magnetic separator for 1 min. The HEK 293 cell lysate supernatant was then added to the magnetic beads. The suspension was incubated on an end-over-end shaker for 1 h at 4 °C. After 1 h, the complexes were washed with wash buffer once, and the wash buffer was removed as described above. The potential interaction proteins with His-tagged rod PDEgamma were eluted with elution buffer containing 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0, and collected for detection by SDS-PAGE/Western blot.

Immunoprecipitation Assay-- The medium was removed, and cells were lysed in ice-cold lysis buffer ((1 ml) containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1% (v/v) Nonidet P-40, 1% (w/v) deoxycholate, 0.1% (w/v) SDS, 10% (v/v) glycerol, 1 mg/ml bovine serum albumin, 20 mM Tris-HCl, 0.5 mM sodium orthovanadate, 0.2 mM PMSF, leupeptin, pepstatin, and aprotinin (all protease inhibitors were at 10 µg/ml, pH 8.0)) for immunoprecipitation. The cells were harvested and centrifuged at 13,000 rpm for 5 min at 4 °C. The concentration of cell lysate supernatant was determined and equalized by performing Bradford colorimetric assay (0.5-1 mg/ml). Cell lysate supernatant was electrophoresed in polyacrylamide gel as positive control.

For immunoprecipitation assay, cell lysate supernatant (500 µl) was taken for immunoprecipitation with specific antibodies (2 µg of antibodies and 100 µl of 1:1 protein A-Sepharose CL4B; 1:1 indicates equal part of protein A-Sepharose and immunoprecipitation buffer). After agitation for 2 h at 4 °C, the immune complex was collected by centrifugation at 13,000 rpm for 15 s at 4 °C. Immunoprecipitates were washed twice with ice-cold buffer A (containing 10 mM Hepes, pH 7.0, 100 mM NaCl, 0.2 mM PMSF, 10 µg/ml leupeptin, 20 µg/ml aprotinin, and 0.5% (v/v) Nonidet P-40) and once in buffer A without Nonidet P-40. The immunoprecipitates were resuspended in boiling sample buffer containing 62 mM Tris-HCl, pH 6.7, 1.25% (w/v) SDS, 10% (v/v) glycerol, 3.75% (v/v) mercaptoethanol, and 0.05% (w/v) bromphenol blue. The samples were then subjected to SDS-PAGE and Western blotting.

Blotting-- Western blotting for phosphorylated p42/p44 MAPK, c-Src, GRK2, Grb-2, dynamin II, and PDEgamma was as described previously (21). Immunoreactive proteins were visualized using enhanced chemiluminescence detection kit.

p42/p44 MAPK Assays-- The phosphorylated forms of p42/p44 MAPK were detected by Western blotting cell lysates with anti-phospho-p42/p44 MAPK antibody. Anti-p42 MAPK antibody was used to establish equal loading of p42 MAPK in each sample.

Quantification-- Quantification was by densitometry.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Interaction between PDEgamma , GRK2, and c-Src-- The ability of GRK2 to phosphorylate PDEgamma in an EGF-dependent manner prompted us to investigate whether these proteins exist in a complex in HEK 293 cells. In addition, several reports (23) have shown that growth factors activate c-Src and GRK2 and that these proteins regulate each other in a bi-directional manner. Moreover, in previous studies (21) we reported that the overexpression of GRK2 and/or PDEgamma increases the activation of p42/p44 MAPK induced by EGF. Therefore, HEK 293 cells were transfected with PDEgamma plasmid constructs and PDEgamma , c-Src, and GRK2 immunoprecipitated with specific respective antibodies from lysates of cells treated with and without EGF. We report here that PDEgamma and c-Src exist in a pre-formed complex and that stimulation of cells with EGF promotes association of GRK2 with the PDEgamma -c-Src complex. This was based upon several lines of evidence. First, Fig. 1a shows that recombinant overexpressed PDEgamma (14 kDa) and c-Src (60 kDa) are co-immunoprecipitated with GRK2 (85 kDa) from lysates of HEK 293 cells using anti-GRK2 antibodies. The amount of both c-Src and recombinant PDEgamma co-immunoprecipitated with GRK2 was increased from cells treated with EGF (fold stimulations in response to EGF: c-Src, 2.74 ± 1.26-fold; PDEgamma , 1.75 ± 0.05-fold, n = 3, p < 0.05 versus control). The EGF-dependent increase in the amount of c-Src and PDEgamma retrieved in anti-GRK2 immunoprecipitates is entirely to be expected if c-Src and PDEgamma are indeed pre-complexed, and EGF stimulation of cells promotes their association with GRK2. The data obtained are therefore entirely compatible with this model. Second, Fig. 1b shows that PDEgamma and GRK2 were co-immunoprecipitated with c-Src using anti-c-Src antibodies. The amount of PDEgamma co-immunoprecipitated was not increased from cells treated with EGF. In contrast, the amount of GRK2 associated with c-Src was increased from cells treated with EGF (fold stimulations in response to EGF: GRK2, 1.85 ± 0.12-fold, GRK2 plus recombinant overexpressed PDEgamma , 1.47 ± 0.21-fold, n = 3, p < 0.05 versus control). In addition, there is a 3.05 ± 0.64-fold increase (n = 2) in the amount of GRK2 associated with c-Src in cells overexpressing PDEgamma compared with cells expressing only endogenous PDEgamma . The fact that the association of PDEgamma with c-Src is not sensitive to EGF stimulation provides additional evidence that these proteins are in a pre-formed complex that is strictly EGF-independent. The increased amount of GRK2 in anti-c-Src immunoprecipitates isolated from cells treated with EGF provides additional evidence that it is the binding of GRK2 to the PDEgamma -c-Src complex that is, in fact, EGF-dependent. We also found that Grb-2 (26 kDa) was co-immunoprecipitated with c-Src, indicating association between these proteins. This association was also increased in cells transfected with PDEgamma . Third, Fig. 1c shows that c-Src and GRK2 were co-immunoprecipitated with PDEgamma from lysates. The amount of c-Src co-immunoprecipitated with PDEgamma using anti-PDEgamma antibodies was not increased from cells treated with EGF. Again, this is entirely in line with our interpretation that the c-Src-PDEgamma complex is pre-formed in an EGF-independent manner. The amount of GRK2 co-immunoprecipitated with PDEgamma was increased from cells treated with EGF (fold stimulations in response to EGF: GRK2, 2.01 ± 0.82-fold, n = 3, p < 0.05 versus control), again indicating that it is the GRK2 binding step that is EGF-dependent. None of the proteins were co-immunoprecipitated when antibodies were omitted from the immunoprecipitation procedure (data not shown).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Interactions of rod PDEgamma with GRK2, c-Src, and Grb2 in HEK 293 cells. HEK 293 cells were transiently transfected with vector, pRK5-GRK2, or rod PDEgamma pcDNA-6xHis plasmid constructs. The cells were then stimulated with EGF (50 ng/ml) for 5 min. a, Western blots (WB) showing co-immunoprecipitation of rod PDEgamma and c-Src with GRK2 from control and EGF-stimulated transfected cells using anti-GRK2 antibodies (Ab). b, co-immunoprecipitation of GRK2, rod PDEgamma , and Grb2 with c-Src from control and EGF-stimulated transfected cells using anti-c-Src antibodies. c, co-immunoprecipitation of c-Src and GRK2 with rod PDEgamma from control and EGF-stimulated transfected cells using anti-C-terminal PDEgamma antibodies. a-c, HEK 293 cell lysates (CL) were used as positive control for the various proteins, run on the same SDS-PAGE as the immunoprecipitates (IP). d, Western blots showing the effect of recombinant rod PDEgamma and GRK2 on the EGF-dependent activation of p42/p44 MAPK in transfected cells. e, Western blots showing the effect of PP2 on the EGF-dependent activation of p42/p44 MAPK in vector- and rod PDEgamma -transfected cells. The cells were pretreated with c-Src inhibitor, PP2 (10 µM, 15 min). f, Western blot of anti-PDEgamma immunoprecipitates with anti-phospho-p42/p44 MAPK antibodies. For d, blots were also stripped and re-probed with anti-p42 MAPK antibodies to ensure equal protein loading. These are representative results of an experiment performed three times.

Only a small fraction of PDEgamma is present in the complex with c-Src and GRK2 (see Fig. 1, a and b compared with c). Thus, only a limited increase in the expression of this protein is actually required to bind c-Src and GRK2 in order to support EGF receptor signaling. This is corroborated by previous findings (21) showing that PDEgamma is limiting for EGF receptor signaling to p42/p44 MAPK. The current findings are also compatible with the fact that cells are stimulated with a single agonist that might use only a relatively small fraction of the PDEgamma expressed. The fold increases in the EGF-dependent association of GRK2 with the c-Src-PDEgamma complex reported here are also in agreement with the potentiation of EGF-stimulated p42/p44 MAPK activation by PDEgamma (see Fig. 1d). In addition to the recombinant form of the protein, we have also reported previously (21) that endogenous PDEgamma participates in regulating EGF receptor signaling to p42/p44 MAPK. This was supported by data showing that the effect of endogenous PDEgamma can be ablated by transfection of cells with PDEgamma antisense plasmid construct (21). Endogenous PDEgamma , c-Src, and GRK2 clearly form a complex in cells, as significant amounts of these proteins were isolated in anti-Src immunoprecipitates from vector-transfected cells (Fig. 1b). As with overexpressed recombinant PDEgamma , EGF promoted the association of GRK2 with endogenous PDEgamma in this complex (Fig. 1b).

Our findings are important because they are the first to define a role for PDEgamma as a functional linker between GRK2 and c-Src. Thus, PDEgamma may function to recruit GRK2 close to c-Src, whereupon there may be the reciprocal activation of each kinase. This functional interaction between PDEgamma , GRK2, and c-Src is important because the formation of the complex appears to be required for EGF-dependent activation of p42/p44 MAPK. Thus, overexpression of PDEgamma or GRK2 increased EGF-dependent activation of p42/p44 MAPK (Fig. 1d, fold stimulations in response to EGF versus vector-transfected cells: rod PDEgamma , 1.7 ± 0.1; GRK2, 1.8 ± 0.2, n = 3, p < 0.05 versus vector-transfected cells), whereas pretreatment of cells with the c-Src inhibitor, PP2, ablated EGF-dependent activation of p42/p44 MAPK (Fig. 1e). We have also obtained additional evidence for a mechanistic link between c-Src-PDEgamma and p42/p44 MAPK. We report here that the p42/p44 MAPK activated in response to EGF associates with the c-Src-PDEgamma complex. Thus, phosphorylated p42/p44 MAPK is present in anti-PDEgamma immunoprecipitates with PDEgamma , c-Src, and GRK2 from vector- and PDEgamma -transfected cells treated with EGF but not from control cells (Fig. 1f). These data strongly suggest that the inhibition of the pool of PDEgamma associated c-Src by PP2 is directly responsible for the attenuation of the EGF-dependent activation of p42/p44 MAPK by this compound. The results therefore further highlight the physiological significance of the PDEgamma -c-Src complex in regulating this kinase pathway. These findings also suggest that the PDEgamma -c-Src-GRK2 complex might undergo endocytosis and relocalization with components of the p42/p44 MAPK pathway.

Role of Thr-62 in PDEgamma Interaction with c-Src and GRK2-- In previous studies we reported that GRK2 phosphorylates PDEgamma on Thr-62. Thus, mutagenesis of the Thr-62 (to Ala) produces a protein whose phosphorylation by GRK2 is severely impeded (21). Mutagenesis of the Thr-62 in PDEgamma has no impact on the folding of this protein, which exists in solution as a polypeptide without tertiary structure. In contrast with wild type PDEgamma , the Thr-62 mutant cannot support EGF-dependent activation of p42/p44 MAPK and, indeed, functions as a dominant negative to block the involvement of endogenous PDEgamma in regulating p42/p44 MAPK signaling (Fig. 2a, fold stimulations of p42/p44 MAPK in response to EGF versus vector-transfected cells: rod PDEgamma , 1.6 ± 0.34; Thr-62 PDEgamma , 0.54 ± 0.02-fold, n = 3, p < 0.05 versus vector-transfected cells). We now show that the mutant PDEgamma is not an efficient binding partner of GRK2 in cells stimulated with EGF when compared with wild type PDEgamma (Fig. 2b). Consistent with this, we found that the amount of GRK2 associated with c-Src was reduced by 52 ± 30% (n = 3, p < 0.05 versus vector transfected cells) in EGF-stimulated cells overexpressing Thr-62 mutant PDEgamma compared with vector-transfected cells. This finding indicates that the mutant might prevent GRK2 binding to endogenous PDEgamma (Fig. 2b). How can this be achieved? One possibility is that the Thr-62 mutant might act as a sink for c-Src, thereby preventing interaction of c-Src with GRK2 via endogenous PDEgamma . Consistent with this possibility is our finding that the Thr-62 mutant was still capable of binding c-Src. Thus, the amount of wild type or Thr-62 mutant PDEgamma co-immunoprecipitated with c-Src was similar (Fig. 2b). Mutation of Thr-62 in PDEgamma also reduced the interaction between the c-Src and Grb-2 (Fig. 2b).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   The role of GRK2 phosphorylation of rod PDEgamma in multiprotein complex formation in HEK 293 cells. HEK 293 cells were transiently transfected with vector or rod PDEgamma or Thr-62 rod PDEgamma mutant pcDNA-6xHis plasmid constructs. The cells were then stimulated with EGF (50 ng/ml) for 5 min. a, Western blots (WB) showing the effect of wild type and Thr-62 PDEgamma on EGF-dependent p42/p44 MAPK activation. Blots were also stripped and re-probed with anti-p42 MAPK antibodies (Ab) to ensure equal protein loading. b, co-immunoprecipitation of GRK2, rod PDEgamma , and Grb2 with c-Src from control and EGF-stimulated transfected cells using anti-c-Src antibodies. HEK 293 cell lysates (CL) were used as positive control and run on the same SDS-PAGE as the immunoprecipitates. These are representative results of an experiment performed three times.

Short Cone PDEgamma -- We have also detected transcript for a short cone PDEgamma isoform, which has a 41-bp deletion (corresponding to exon 3) resulting in a frame change (22). This deletion produces a new "in-frame" stop codon resulting in an early termination to produce a truncated protein (short cone PDEgamma ) that lacks Thr-62. This protein is predicted to have an identical N-terminal and polycationic mid-region but a different C-terminal domain compared with the larger version of cone PDEgamma .

We have therefore investigated the effect of the truncated recombinant cone PDEgamma on p42/p44 MAPK signaling. Overexpression of the truncated cone PDEgamma reduced the EGF-dependent activation of p42/p44 MAPK (Fig. 3, upper panel, fold stimulations of p42/p44 MAPK in response to EGF versus vector-transfected cells: rod PDEgamma , 1.6 ± 0.34; short cone PDEgamma ; 0.59 ± 0.27; rod PDEgamma plus short cone PDEgamma ; 1.15 ± 0.06, n = 3-6, p < 0.05 for rod PDEgamma plus short cone PDEgamma -transfected versus rod PDEgamma -transfected cells).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   The effect of the truncated cone PDEgamma on the EGF/thrombin-dependent activation of p42/p44 MAPK. HEK 293 cells were transiently transfected with vector or truncated cone PDEgamma and/or rod PDEgamma and/or cone PDEgamma pcDNA-3.1 plasmid constructs. The cells were then stimulated with EGF (50 ng/ml, 5 min) or thrombin (0.03 unit/ml, 10 min). Western blots (WB) showing upper panel, the EGF-stimulated p42/p44 MAPK activation in rod PDEgamma - and/or truncated cone PDEgamma -transfected cells; lower panel, thrombin-stimulated p42/p44 MAPK activation in rod PDEgamma - and/or cone PDEgamma - and/or truncated cone PDEgamma -transfected cells. p42/p44 MAPK activation was detected using anti-phospho-p42/p44 MAPK-specific antibodies (Ab). Blots were also stripped and re-probed with anti-p42 MAPK antibodies to ensure equal protein loading. These are representative results of an experiment performed three times.

The increase in thrombin-dependent activation of p42/p44 MAPK induced by either rod or large cone PDEgamma was also reduced in cells overexpressing the truncated cone PDEgamma (Fig. 3, lower panel, fold stimulations of p42/p44 MAPK in response to thrombin versus vector-transfected cells: rod PDEgamma , 2.3 ± 0.2; cone PDEgamma , 2.05 ± 0.18; short cone PDEgamma , 0.77 ± 0.15; short cone PDEgamma plus rod PDEgamma , 0.95 ± 0.03; short cone PDEgamma plus cone PDEgamma , 0.84 ± 0.12, n = 3-6, p < 0.05 for rod or cone PDEgamma plus short cone PDEgamma -transfected versus rod or cone PDEgamma -transfected cells). Thus, the truncated cone PDEgamma may also act as an endogenous dominant negative modulator of EGF- and thrombin-dependent stimulation of the p42/p44 MAPK pathway.

PDEgamma -PDEgamma Interaction-- One of the structural determinants in PDEgamma that may be important for association with c-Src is an SH3-binding site. PDEgamma contains an SH3 consensus binding site 20PVTPRKGPP28, which is identical with the corresponding region in the cone isoform with the exception that valine at amino acid position 21 is replaced by threonine. This site may therefore interact with an SH3 domain in c-Src. In previous studies (21) we reported that thrombin also promotes the association of PDEgamma with dynamin II. This might also involve interaction of dynamin II SH3-binding site via an intermediate double SH3 domain containing protein (e.g. Grb-2) with 20PVTPRKGPP28 in PDEgamma . Thus, PDEgamma might bind several proteins via SH3 interaction. Indeed, along with c-Src and GRK2, dynamin II is involved in endocytic processes that are required for certain GPCR/growth factor-dependent activations of p42/p44 MAPK (4-11). However, PDEgamma contains only one SH3 domain binding site. It is therefore possible that PDEgamma might form either dimers or tetramers, thereby increasing the number of SH3 domain binding sites from 1 to 4. Indeed, it is well established that PDEgamma forms dimers via hydrophobic interaction, and indeed, two molecules of PDEgamma bind to PDE6 in rod photoreceptors (18). To assess this possibility, we immobilized His-tagged PDEgamma on a nickel-agarose matrix in order to capture endogenous PDEgamma -c-Src-Grk2 complexes present in lysates from HEK 293 cells. Fig. 4a shows that GRK2 (85 kDa), c-Src (60 kDa), dynamin II (112 kDa), and Grb-2 (26 kDa) in lysates from control cells were all trapped by the His-tagged PDEgamma -agarose matrix and eluted with imidazole. The amount of each of these proteins binding to the His-tagged PDEgamma -agarose matrix was increased from lysates of cells treated with EGF (fold stimulations in response to EGF versus control cells: GRK2, 1.73 ± 0.51-fold; dynamin II, 1.53 ± 0.18-fold; Grb-2, 1.47 ± 0.14-fold; c-Src, 1.45 ± 0.11-fold, n = 3, p < 0.05 for all versus control). PDEgamma was also eluted with imidazole from the nickel matrix (Fig. 4b). The fold increases in the binding of the various proteins are all similar. This is entirely consistent with the possibility that EGF treatment of cells might promote the binding of the entire complex of proteins to PDEgamma immobilized on the nickel matrix. Taken together, these findings suggest that EGF may increase the affinity of PDEgamma for PDEgamma - protein complexes.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   The EGF-dependent effect on the interaction between immobilized PDEgamma and PDEgamma -dynamin II-GRK2-c-Src-Grb-2 complexes. Recombinant His-tagged bacterially expressed rod PDEgamma was immobilized on Ni-NTA magnetic agarose beads by preincubating the bacterial lysates with magnetic beads. HEK 293 cells were treated with or without EGF (50 ng/ml) for 5 min. HEK 293 cell lysates were then incubated with Ni-NTA magnetic agarose beads-His-tagged rod PDEgamma . HEK 293 cell lysates (both control and EGF-stimulated) were separated by SDS-PAGE and serve as positive control to determine the migration of specific proteins. The protein complexes were eluted with 250 mM imidazole elution buffer. a, Western blotting (WB) of imidazole eluates with antibodies (Ab) to dynamin II, GRK2, c-Src, and Grb2; b, Western blotting of imidazole eluates with anti-C-terminal rod PDEgamma antibodies. These are representative results of an experiment performed three times.

We conclude that the stimulation of cells with EGF might induce three events. First, EGF promotes association of GRK2 with the c-Src-PDEgamma complex. Second, EGF promotes GRK2-catalyzed phosphorylation of PDEgamma ; and third, the growth factor may increase the affinity of PDEgamma for PDEgamma . This may promote formation of a dimeric or tetrameric PDEgamma platform upon which other proteins involved in endocytic signaling to p42/p44 MAPK, such as dynamin II, can associate.

Negative Feedback Regulation by p42/p44 MAPK-- The 20PVTPRKGPP28 site in rod PDEgamma also contains a consensus site for phosphorylation by p42/p44 MAPK (20PVTP23). Indeed, we found that this site was phosphorylated by p42/p44 MAPK. Paglia and colleagues (24) have formerly reported stoichiometric phosphorylation of PDEgamma by p42 MAPK. Therefore, we have mutated Thr-22 to establish its effect on PDEgamma -mediated regulation of p42/p44 MAPK. For this purpose we used cultured airway smooth muscle cells. These cells contain abundant amounts of PDEgamma (18), such that the protein is saturating for EGF-stimulated p42/p44 MAPK activation (data not shown). Transfection of these cells with Thr-22 mutant PDEgamma -pcDNA3.1 plasmid construct led to a prolonged activation of p42/p44 MAPK by EGF compared with vector (H)-transfected cells (Fig. 5). These data are compatible with the possibility that p42/p44 MAPK can phosphorylate PDEgamma at Thr-22 to exert the feedback inhibition of PDEgamma -c-Src/GRK2 activity, thereby limiting the duration of p42/p44 MAPK activation in response to EGF. Presumably, mutagenesis of Thr-22 to Ala does not in itself disrupt interaction between PDEgamma , c-Src, and GRK2, as this mutant is still capable of supporting activation of p42/p44 MAPK in response to EGF. Indeed, the mutant is more efficient compared with the endogenous wild type PDEgamma . In this case, the Thr-22 mutant presumably replaces endogenous wild type PDEgamma in the signaling pathway regulating p42/p44 MAPK.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 5.   The Thr-22 mutant PDEgamma functions to prolong EGF-dependent activation of p42/p44 MAPK in airway smooth muscle cells. ASM cells were transiently transfected with vector (H) or rod PDEgamma and/or Thr-22 mutant rod PDEgamma pcDNA-3.1 plasmid constructs. The cells were then stimulated with EGF (50 ng/ml) for the indicated times. Western blots showing the time course of EGF-stimulated p42/p44 MAPK activation in vector or rod PDEgamma - or Thr-22 mutant rod PDEgamma -transfected cells. p42/p44 MAPK activation was detected using anti-phospho-p42/p44 MAPK specific antibodies. Blots were also stripped and re-probed with anti-p42 MAPK antibodies to ensure equal protein loading. These are representative results of an experiment performed three times.

To conclude, these findings highlight an important role for PDEgamma in transducing signals from GRK2/c-Src to p42/p44 MAPK. They also demonstrate that PDEgamma functions as an important intermediate regulating this mitogenic signaling pathway.

    FOOTNOTES

* This work was supported by grants from The Wellcome Trust.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 0141-552-4400 (ext. 2659); Fax: 0141-552-2562; E-mail: n.j.pyne@strath.ac.uk.

Published, JBC Papers in Press, March 6, 2003, DOI 10.1074/jbc.M212103200

    ABBREVIATIONS

The abbreviations used are: GPCR, G-protein-coupled receptor; EGF, epidermal growth factor; GRK, G-protein coupled receptor kinase; Grb-2, growth factor receptor-binding protein; HEK, human embryonic kidney; MAPK, mitogen activated protein kinase; PDE, phosphodiesterase; PDGF, platelet-derived growth factor; SH3, Src homology 3; PMSF, phenylmethylsulfonyl fluoride; Ni-NTA, nickel-nitrilotriacetic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
2. Van Biesen, T., Hawes, B. E., Luttrell, D., Kreuger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995) Nature 376, 781-784[CrossRef][Medline] [Order article via Infotrieve]
3. Luttrell, L. M., Daaka, Y., and Lefkowitz, R. J. (1999) Curr. Opin. Cell Biol. 11, 177-183[CrossRef][Medline] [Order article via Infotrieve]
4. Luttrell, L., Van Biesen, T., Hawes, B. E., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 16495-16498[Abstract/Free Full Text]
5. Hallak, H., Seiler, E. M., Green, J. S., Ross, B. N., and Rubin, R (2000) J. Biol. Chem. 275, 2255-2258[Abstract/Free Full Text]
6. Fedorov, Y. V., Jones, N. C., and Olwin, B. B. (1998) Mol. Cell. Biol. 18, 5780-5787[Abstract/Free Full Text]
7. Rakhit, S., Pyne, S., and Pyne, N. J. (2000) Mol. Pharmacol. 58, 413-420[Abstract/Free Full Text]
8. Conway, A.-M., Rakhit, S., Pyne, S., and Pyne, N. J. (1999) Biochem. J. 337, 171-177[CrossRef][Medline] [Order article via Infotrieve]
9. Rakhit, S., Pyne, S., and Pyne, N. J. (2001) Mol. Pharmacol. 60, 63-70[Abstract/Free Full Text]
10. Alderton, F., Rakhit, S., Kong, C. K., Palmer, T., Sambi, B., Pyne, S., and Pyne, N. J. (2001) J. Biol. Chem. 276, 28578-28585[Abstract/Free Full Text]
11. Dalle, S., Ricketts, W., Imamura, T., Vollenweider, P., and Olefsky, J. M. (2001) J. Biol. Chem. 276, 15688-15695[Abstract/Free Full Text]
12. Wang, H., Doronin, S., and Malbon, C. C. (2000) J. Biol. Chem. 275, 36086-36093[Abstract/Free Full Text]
13. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. G., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688[Abstract/Free Full Text]
14. Ahn, S., Maudsley, S., Luttrell, L. M., Lefkowitz, R. J., and Daaka, Y. (1999) J. Biol. Chem. 274, 1185-1188[Abstract/Free Full Text]
15. Lin, F.-T., Daaka, Y., and Lefkowitz, R. J. (1999) J. Biol. Chem. 273, 31640-31643[Abstract/Free Full Text]
16. Ferguson, S. S. G., Downey, W. E., III, Colapietro, A.-M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363-366[Abstract]
17. Clague, M. J. (1998) Biochem. J. 336, 271-282[Medline] [Order article via Infotrieve]
18. Stryer, L. (1991) J. Biol. Chem. 266, 10711-10714[Free Full Text]
19. Lochhead, A., Nekrasova, E., Arshavsky, V. Y., and Pyne, N. J. (1997) J. Biol. Chem. 272, 18397-184903[Abstract/Free Full Text]
20. Tate, R., Lochhead, A., Brzeski, H., Arshavsky, V. Y., and Pyne, N. J. (1998) Cell Biochem. Biophys 29, 133-144[CrossRef][Medline] [Order article via Infotrieve]
21. Wan, K.-F., Sambi, B., Frame, M., Tate, R. J., and Pyne, N. J. (2001) J. Biol. Chem. 276, 37802-37808[Abstract/Free Full Text]
22. Tate, R. J., Arshavsky, V. Y., and Pyne, N. J. (2002) Genomics 79, 582-586[CrossRef][Medline] [Order article via Infotrieve]
23. Sarnago, S., Elorza, A., and Mayor, F., Jr. (1999) J. Biol. Chem. 274, 34411-34416[Abstract/Free Full Text]
24. Paglia, M. J., Mou, H., and Cote, R. H. (2002) J. Biol. Chem. 277, 5017-5023[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.